Market research
PTN Palatin Technologies, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17M
- P/E ratio
- 88.09
- Analyst target
- 53.5
- Dividend yield
- Not available
- Beta
- -0.1
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6960776010
- Market cap
- 17M
- P/E ratio
- 88.09
- Analyst target
- 53.5
- Dividend yield
- Not available
- Beta
- -0.1
About
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PTN discussion.
5 years, 4 months ago
Palatin Technologies, Inc is currently in a long term downtrend where the price is trading 6.5% below its 200 day moving average.
From a valuation standpoint, the stock is 40.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 792.2.
Palatin Technologies, Inc's total revenue sank by 895.6% to $-164K since the same quarter in the previous year.
Its net income has dropped by 90.6% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 189.3% to $-14M since the same quarter in the previous year.
Based on the above factors, Palatin Technologies, Inc gets an overall score of 1/5.